ADPS™
EGFR Mutation Test Kit v1
Supporting precision medicine for more patients
Supporting precision medicine for more patients
EGFR is a membrane protein that transmits signals that promote cell growth and proliferation, and is strongly associated with certain types of cancer. EGFR mutations are identified in approximately 20% NSCLC patients in Western populations and 40 to 55% of NSCLC patients in East Asian populations. Most EGFR mutations occur in exons 18–21.
EGFR mutations are targeted by specific tyrosine kinase inhibitors (TKIs), and the EGFR T790M mutation is used as a resistance biomarker. Therefore, the analysis of EGFR mutations in NSCLC patients can help personalize treatment for patients.
The ADPS™ EGFR Mutation Test Kit v1 detects 44 mutations in exons 18 to 21 of the EGFR gene with a detection sensitivity ranging from 0.01% to 0.1%. It is designed to allow testing of both tissue and plasma samples with a single kit.
In Europe, medical professionals can prescribe EGFR TKI based on the analysis results. In other regions, it is for research use only (RUO) and cannot be used in diagnostic procedures.
| Catalog No. | (IVD) D8000APA (RUO) R8000APA |
|---|---|
| Detection target | 44 mutations in EGFR exon 18, 19, 20 and 21 |
| Assay type | qPCR |
| Sample type | DNA extracted from FFPE, frozen, and fresh cancer tissue or liquid biopsy |
| Master Mixture (MMX) |
4MMXs |
| Internal Control | EGFR exon 4 |
| Detection Sensitivity | 0.01~0.1%(FFPET), 10~60copies/mL(plasma) |
| Detection Specificity | ≥ 99% |
| Precision (% CV) | ≤ 5% (CV, coefficient of variation) |
| Storage | -20±5℃ |
| Stability | 18 months |
| Freeze/Thaw stability | 5 times |
| Compatible Instruments | IVD - AB7500Fast / |
| RUO – AB7500Fast, CFX96, Roter-Gene Q, | |
| LightCycler 480, QuantStudio 5 |
ADPS™ Oncogene Mutation Test